医学
队列
抗磷脂综合征
优势比
内科学
家族史
逻辑回归
儿科
回顾性队列研究
免疫学
血栓形成
作者
Patricia Morán‐Álvarez,Á. Andreu-Suárez,Liz Caballero-Mota,Susanna Gassiot-Riu,Rubén Berrueco-Moreno,Joan Calzada-Hernández,Jordi Anton-López,Mónica Vázquez-Díaz,Alina Boteanu
出处
期刊:Rheumatology
[Oxford University Press]
日期:2022-02-08
卷期号:61 (11): 4465-4471
标识
DOI:10.1093/rheumatology/keac070
摘要
Abstract Objective To identify the variables associated with the development of non-criteria manifestations in the presence of antiphospholipid antibodies (aPLs) in a paediatric cohort. Methods Multicentric historical cohort study of children under the age of 18 years to determine thrombotic events (TEs) and non-criteria manifestations in the presence of aPL. Results Eighty-two children were included; 8.5% had at least one TE and 69.5% at least one non-criteria manifestation. Of them, 96.5% did not associate TEs. Haematological manifestations were the most frequent (43.65%), followed by cutaneous (22%), neurological (15.9%) and cardiac (4.9%) events. The most frequent aPLs were: 77.8% LA; 42.7% aCL and 41.5% aβ2GP. The positivity rate was: 64.6% simple, 18.3% double and 17.1% triple. ANA positivity was 68.1%. A bivariate analysis revealed that children with IgM aCL+, IgM aβ2GP+, ANA+, an SLE diagnosis or the absence of TEs had a significantly higher percentage of non-criteria manifestations (P <0.05). The logistic regression showed family history of autoimmune diseases [odds ratio (OR) 4.26, 95% CI: 0.8, 22.2, P =0.086] and the absence of TEs (OR 17.18, 95% CI: 1.2, 244.6, P =0.03) as independent risk factors of developing non-criteria manifestations. An SLE diagnosis, aPL profile and ANA+ were not identified. Conclusion Non-criteria manifestations were more frequent than TEs. A positive family history of autoimmune diseases and the absence of TEs were associated with a higher risk of developing non-criteria manifestations. Therefore, their inclusion as APS classification criteria should be considered in order to get an improved prognosis in the paediatric population.
科研通智能强力驱动
Strongly Powered by AbleSci AI